Main-stay in treatment of leishmaniasis relies on chemotherapy but none of the current drugs combines high activity and low toxicity at affordable costs. Dinitroanilines are a new class of drugs with proved in vitro antileishmanial activity. However the development of their pharmaceutical formulations has been compromised by low water solubility and low accumulation in diseased organs. These limitations can be overcome by incorporation in lipid-based nanoformulations such as liposomes and solid lipid nanoparticles. In previous work this strategy was already followed with the incorporation of a dinitroaniline, oryzalin, resulting in the improvement of the biodistribution profile. The present work aims at demonstrating the in vitro and in vivo therapeutic activity of these oryzalin nanoformulations, and establishing a systematic comparison of both systems. After oryzalin incorporation suitable physicochemical properties for parenteral administration were obtained. Nanoformulations revealed reduced cytotoxicity and haemolytic activity when compared with free-oryzalin, while retaining the in vitro intracellular activity. Therapeutic activity, assessed in a murine model of visceral leishmaniasis, was evaluated in terms of number of administrations, dose-response and influence of the lipid excipient. Results demonstrate the superiority of both oryzalin nanoformulations on the reduction of parasitic burden in liver and spleen as compared to the control group (84 to 91%) and similar to Glucantime ® . A strong reduction in ED 50 values (3 to 65 fold) as compared to free-oryzalin was also obtained, depending on the organ and nanoformulation used. Both oryzalin nanoformulations are potential candidates as therapeutic agents against visceral leishmaniasis.
INTRODUCTION
Leishmaniasis, a neglected tropical disease caused by protozoa parasites of the genus Leishmania, is characterised by diverse and complex clinical manifestations ranging from skin lesions to serious disfigurement and fatal systemic infection. 1 The disease is caused by the infective promastigote form of the parasite that multiply as amastigotes within cells of the mononuclear phagocytic system (MPS), mainly macrophages. Despite infecting around 14 million people worldwide in 98 countries and with more than 350 million people at risk of infection, to date no effective vaccine is available and control strategies rely primarily on chemotherapy to alleviate the disease and has already proved to be active against several types of pathogenic protozoa, such as Trypanosoma spp., 6 Leishmania spp. [7] [8] [9] and Plasmodium falciparum. 10 The potential of dinitroanilines as antiparasitic agents arises from their selectivity to protozoan parasites tubulin and lack of binding affinity to mammalian tubulin making these molecules safe to animals. 11 Their antileishmanial properties were first described by Chan et al. 11 who showed that one dinitroaniline, trifluralin (TFL), inhibited the proliferation and differentiation of L. amazonensis. It was also proved that another dinitroaniline, oryzalin (ORZ), is active in vitro against Leishmania strains responsible for visceral (VL) 7 9 and cutaneous leishmaniasis. 8 Despite this anticipated antileishmanial potential, the development of pharmaceutical formulations of active dinitroanilines for parenteral administration has been compromised due to its low water solubility 12 and low accumulation in the diseased organs. 13 These features pose a major challenge to their pharmaceutical formulation and clinical application. 14 The association of these agents with suitable nano drug delivery systems (nanoDDS) represents a strategy not only to overcome these problems, but also to improve the therapeutic index while reducing potential side effects of this drug.
One of the most extensively used lipid-based nanoDDS able to promote a selective and targeted delivery of various therapeutic agents are liposomes. 15 These phospholipidic vesicles are suitable carriers for antileishmanial drugs as they are naturally taken up by macrophages in the liver and in the spleen, 16 the main reservoirs of Leishmania parasites. The use of liposomal formulations resulted in a substantial increase of antileishmanial activity of several drugs as compared to the free drug. [17] [18] [19] [20] Nevertheless, the potential advantages of using nanoDDS for current antileishmanial drugs may be limited by the pre-existence of resistance to those drugs (e.g., pentavalent antimonials or miltefosine) or by prohibitive high costs (liposomal amphotericin B). 21 22 Two dinitroanilines, TFL and ORZ, are new therapeutic agents that present potential antileishmanial properties that could be enhanced by their association with nanoDDS. Carvalheiro et al. 23 24 have developed liposomal formulations of TFL that demonstrated a superior antileishmanial activity as compared to the free drug in a murine model of VL (L. donovani) and in the treatment of experimental canine leishmaniasis (L. infantum). 24 Furthermore Lopes et al. 25 reported the incorporation of ORZ in appropriate liposomal formulations. These new ORZ formulations were responsible for an increased ORZ solubility and an increased delivery of the drug to the main organs of leishmanial infection. 13 Nevertheless the in vitro and in vivo therapeutic activity of ORZ liposomes (Lip-ORZ) was not demonstrated, being one of the objectives of this work. Another objective was the clarification of possible advantages on using other type of lipid-based nanoDDS, solid lipid nanoparticles (LNP), instead of liposomes. These particles, made from a solid lipid core surrounded by a surfactant layer, are a more recent nanoDDS that have gained considerable interest in the last two decades in several research areas. 26 27 The application of LNP on parasitic diseases is still not widely used as liposomes but its value in improving the therapeutic efficiency of known antileishmanial and antimalaria agents has been already reported in previous studies using amphotericin B, 28 artemether 29 and curcuminoids. 30 Although Lopes et al. 25 reported the production of ORZ-containing LNP (LNP-ORZ) there are no studies concerning the in vitro and in vivo therapeutic evaluation of these particles.
The present study describes a systematic comparison of two lipid-based nanoformulations (liposomes and LNP) aiming at improving the in vitro and in vivo performance of ORZ as an antileishmanial agent. This includes, in vitro activity and toxicity and in vivo antileishmanial activity in a VL murine model.
MATERIAL AND METHODS

Materials
ORZ was purchased from Supelco (Bellefonte, USA), and pure phospholipids (dimyristoylphosphatidylcholine-DMPC and dimyristoylphosphoglycerol-DMPG) were supplied by Avanti Polar Lipids, Inc. (Alabaster, USA) and soya lecithin (Lipoid S100) from Lipoid (Ludwigshafen, Germany). Tripalmitin (glyceryl tripalmitate, purity ≥ 85%, melting point 66 C), sodium deoxycholate and Tween ® 20 were obtained from Sigma-Aldrich (Spain). Acetonitrile (HPLC grade) was from Merck. Culture media, foetal bovine serum (FBS) and antibiotics (penicillin-streptomycin) were purchased from Invitrogen Life Technologies (USA). Distilled water was of Milli-Q quality (Millipore, Bedford, MD, USA). All other reagents were of analytical grade and were used without further purification.
Preparation of Lip-ORZ
The incorporation of ORZ in liposomes was performed by the dehydration-rehydration method (DRV) with some modifications. 13 16 31 Briefly, the appropriate amounts of phospholipids (10 mM) and ORZ (0.5 or 1 mM) were dissolved in chloroform and dried on a Büchi rotary evaporator RE-111 (Büchi, Switzerland) until a homogeneous film was formed. The film was dispersed with water, and the resultant suspension was frozen and lyophilised overnight in a Modulyo freeze-dryer (Edwards, Germany). The lyophilised powder was rehydrated in two steps with citrate buffer (10 mM citrate, 145 mM NaCl, pH 5.5): first with 2/10 of the final volume followed by mild vortexing, at room temperature, and then, 30 min after, rehydration was completed with the addition of the remaining volume (8/10 of the final volume) of citrate buffer. The so formed liposomes were then down-sized using an extruder device (LipexBiomembranes, Canada) by sequential extrusion through polycarbonate filters ranging from 0.8 to 0.2 m in pore size until the desired size was obtained. Non-incorporated ORZ was separated from the liposome dispersion by size exclusion chromatography in a PD-10 column (Bio-Rad Laboratories, California, USA) using citrate buffer as eluent. Incorporated ORZ was quantified by high-pressure liquid chromatography (HPLC), using the method described under 2.4.2. Unloaded liposomes were prepared as described above, with the exception that no ORZ was added. For in vitro and in vivo studies, as higher ORZ concentration are needed, the eluted liposomes were concentrated by ultra-centrifugation (250,000 g, 1 h 30 min) in a Beckman L8-60M ultracentrifuge (Beckman Instruments, Inc., USA) and suspended in citrate buffer.
Preparation of LNP-ORZ
The LNP were prepared by the emulsion-solvent evaporation method using tripalmitin as the lipid component and sodium deoxycholate, Tween ® 20 and soya lecithin as co-surfactants. 25 Briefly, tripalmitin and lecithin were dissolved in dichloromethane (organic phase) and then added to the aqueous phase containing the Tween ® 20 and sodium deoxycholate. The dispersion step was performed during a 1 min period of sonication (Branson Sonifier 250, Danbury, USA) followed by 3.5 min at 10,000 rpm using a Silverson High Speed Mixer L5M (Silverson Machines, Chesham, UK). The nanoparticle dispersion was then kept under stirring for approximately 4 h at room temperature until complete evaporation of the dichloromethane. When incorporating ORZ, the drug (2.2 or 4.4 mM) was added to the organic phase. Non-incorporated ORZ was separated from the LNP dispersion by size exclusion chromatography in a PD-10 column (Bio-Rad Laboratories, California, USA) using PBS pH 7.4 as eluent. Incorporated ORZ was quantified by HPLC, using the method described under 2.4.2. For in vitro and in vivo studies, as higher ORZ concentration are needed, the eluted LNP formulations were concentrated after centrifugation (4,000 g, 10 min, × 3) through a membrane concentrator (Amicon ® Ultra-4 centrifugal filter units, 100 KDa MWCO, Millipore, Ireland) and suspended in PBS.
Characterisation of Nanoformulations Size and Zeta Potential Measurements
Liposome and LNP mean diameter (Ø) and polydispersity index (Pdi) were determined by quasi-elastic laser light scattering in a Malvern Zetasizer Nano S (Malvern Instruments, UK). The zeta potential (surface charge, ) was determined using laser Doppler anemometry in a Nano Z (Malvern Instruments, UK). Samples were appropriately diluted for the measurements. Phospholipid determination of liposomes was performed as described by Rouser et al. 32 based on the quantification of inorganic phosphorous. Tripalmitin and soya lecithin concentrations on LNP were determined by the methods of GPO-POD (glycerol phosphate dehydrogenasePeroxidase) and Trinder, respectively, using enzymatic colorimetric assay kits (Spinreact, Girona, Spain).
ORZ and Lipid Quantification
Incorporation Efficacy and Drug Loading
ORZ nanoformulations were evaluated in terms of incorporation efficacy (I.E.) and drug loading capacity (L.C.) determined as described by the equations below. Cells and Culture Conditions L. infantum promastigotes (MHOM/MA/67/ITMAP-263) kindly provided by Professor Ana Tomás (IBMC, Universidade do Porto) were grown in RPMI-1640 supplemented with 10% FBS, antibiotics and 25 mM HEPES, pH 7.4 at 26 C. The virulence of Leishmania parasites was maintained by passage in BALB/c mice. For in vitro studies, L. infantum promastigotes were transfected by electroporation as previously described 33 to obtain promastigotes expressing green fluorescent protein (GFP). The human monocytic leukaemia THP-1 cell line was used as a host for leishmania parasites. The THP-1 cells were maintained in RPMI-1640 supplemented with 10% FBS, 1 mM HEPES, 2 mM glutamine, antibiotics and 1 mM sodium pyruvate, pH 7.2 at 37 C with 5% CO 2 .
Animals
Balb/c male mice (22-24 g) were obtained from Charles River, Barcelona, Spain. Animals were fed with standard laboratory food and water ad libitum. All experimental animal procedures were carried out with the permission of the local animal ethical committee and licensed by Direção 
Biological Evaluation of ORZ Nanoformulations Haemolytic Potential
The haemolytic activity was determined using EDTApreserved peripheral human blood, according to Esteves et al. 34 Briefly, blood was centrifuged to remove the plasma, and the red blood cells (RBCs) were washed three times in PBS. After the final wash, RBCs were distributed in 96-well microplates (100 L/well) and equal volumes of Lip-ORZ, LNP-ORZ and Free-ORZ (both diluted in PBS in concentrations between 4 and 500 M) were added. After incubation at 37 C for 1 h, the plates were centrifuged (800 g, 10 min) and the supernatants recovered. The absorbance of the supernatant was measured at 540 nm with the reference filter at 620 nm in a microplate reader (ELx800, Biotek, USA). In each plate negative and positive controls were prepared by incubating RBCs with PBS and water, respectively. The absorbance of Lip-ORZ, LNP-ORZ and Free-ORZ solutions was also determined and used as control. The percentage of haemolytic activity of each formulation at different concentrations was estimated using A − A 0 / A max − A 0 × 100, where A 0 is the negative control haemolysis and A max corresponds to 100% haemolysis (positive control). The haemolytic activity was also evaluated by the determination of HC 50 value (drug concentration that lyses 50% of RBCs) calculated by linear regression analysis.
Cytotoxicity
Studies were carried out using the THP-1 human monocytic cell line as described by Plano et al. 35 A quantitative measurement of the cell damage after incubation with different concentrations of ORZ (Lip-ORZ, LNP-ORZ and Free-ORZ) was evaluated by flow cytometry using the propidium iodide (PI) exclusion method. The THP-1 cells during logarithmic growth phase (4 × 10 5 cells/mL) were incubated with concentrations of Lip-ORZ, LNP-ORZ and Free-ORZ ranging from 0.04 to 25 M. After an incubation period of 24 h (37 C, 5% CO 2 ), cells were stained with PI (5 g/mL) and then analysed for PI fluorescence by flow cytometry. The cytotoxicity was evaluated by the determination of CC 50 value (drug concentration that reduced the percentage of viable cells in 50%) calculated by linear regression analysis.
In Vitro Antileishmanial Activity in Promastigote Cultures
In vitro activity in promastigotes cultures was determined using L. infantum promastigotes expressing GFP, according to Plano et al. 35 L. infantum promastigotes expressing GFP during the logarithmic growth phase (2 × 10 5 cells/mL) were incubated with different concentrations of Lip-ORZ, LNP-ORZ and Free-ORZ (0.04-25 M) in 96-well tissue culture plates (Cellstar, Greiner) at 26 C for 24 h. The percentage of viable promastigotes was evaluated by flow cytometry using the PI exclusion method. The activity was evaluated by the determination of IC 50 value (drug concentration that reduced the percentage of viable promastigotes in 50%) calculated by linear regression analysis.
In Vitro Antileishmanial Activity Against the Intracellular L. infantum Intracellular activity was determined according to Plano et al. 35 Briefly, THP-1 cells were seeded in 24 well plates (Nunc, Roskilde, Denmark) and differentiated to macrophages for 24 h in 1 mL of RPMI-1640 medium containing 10 ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA). Culture medium was removed and the macrophages were infected with promastigotes expressing GFP in 1 mL of THP-1 medium (promastigote:macrophage ratio, 5:1) for 5 h at 37 C, 5% CO 2 . After incubation, non-infecting promastigotes were removed; plates were washed two times with 1× PBS and replaced with new RPMI-1640 medium containing different concentrations Lip-ORZ, LNP-ORZ and Free-ORZ (10-50 M). After 72 h treatment, medium was removed; THP-1 cells were washed one time with 1× PBS and detached with TrypLE ™ Express (Invitrogen, Leiden, the Netherlands) according to the manufacturer's indications. Cells were stained with PI and the infection quantification was measured by flow cytometry. The antileishmanial effect was evaluated by the determination of IC 50 value (drug concentration that reduced infection in 50%) calculated by linear regression analysis.
Flow Cytometry Analysis
Cell samples were analysed on a Guava ® easyCyte ™ 5HT flow cytometer and InCyteTM software (Millipore, Bedford, MD, USA), equipped with a 488 nm argon laser. At least 5,000 cells were analysed per sample, and data analysis were performed on fluorescence intensities (GFP: 545 nm and PI: 645 nm) that excluded cell autofluorescence and cell debris.
In Vivo Antileishmanial Activity
The animals were infected by intravenous (i.v.) injection in a lateral tail vein with 200 L of an L. infantum inoculum with 10 6 promastigotes (MHOM/MA/67/ITMAP-263).
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The treatment started one week post-infection (day 7) when the animals were randomly sorted into groups of five mice. Free-ORZ was prepared in a mixture of citrate buffer and Tween ® 80 (95/5% w/w). Study of the effect of administration route: mice were treated with either Lip-ORZ or Free-ORZ (25 mg ORZ/kg/day) by i.v. route of administration for 5 consecutive days (days 7-11).
Study of the effect of number of administrations: mice were treated with Lip-ORZ, LNP-ORZ and Free-ORZ (25 mg ORZ/kg/day) by i.v. route of administration for 5 (days 7-11) or 10 (day 7-11 and 14-18) consecutive days with two days interval in-between. Dose-response relationship: mice were treated with 6.25, 12.5 and 25 mg ORZ/kg/day by i.v. route of administration for 5 consecutive days (days 7-11). ORZ was administered as Lip-ORZ, LNP-ORZ or Free-ORZ.
Study of the effect of lipid excipient: mice were treated with 6.25 mg ORZ/kg/day with different lipid concentrations by i.v. route of administration for 5 consecutive days (days 7-11). ORZ was administered as Lip-ORZ or LNP-ORZ. As a control, unloaded liposomes and LNP (equivalent dose of lipid) were also administered i.v. following the same treatment regimen as the ORZ nanoformulations.
Regardless of the administration route, all nanoformulations were administered in 0.2 mL final volume. In i.v. treatment, ORZ nanoformulations and Free-ORZ were administered in the lateral tail vein.
Evaluation of Parasitic Burden PB in Mice
In all treatment regimens above described animals were sacrificed by cervical dislocation 3 days after the last treatment administration, and spleens and livers were aseptically collected and weighted. Viable PB was determined by the limiting dilution assay (LDA). Briefly, both organs were homogenized in Schneider's Drosophila medium supplemented with 10% heat-inactivated FBS, and then diluted in the same medium to a final concentration of 10 mg/mL. These cell suspensions were then titrated in quadruplicate across a 96-well plate in serial four-fold dilutions (four titrations per organ). After 10 days of growth at 26±1 C, the last dilution containing promastigotes was recorded and the number of parasites per gram of organ (parasite burden) calculated as described by Buffet et al. 37 The suppression of parasite growth was calculated as the percentage inhibition relative to parasitic burden of negative control animals:
where PB Treated represented the PB of the treated animal and PB Control the average PB of the negative control group.
The PB growth index (GI) was calculated using the following formula:
PB Growth index (GI)
= log 10 PB end of treatment − log 10 PB beginning of treatement
Statistical Analysis
Data presented are expressed as mean ± standard deviation (SD), as mentioned in legends of figures and tables. Statistical analysis was performed using one-way ANOVA, with the exception of the data obtained in the in vivo studies which were analysed with a Kruskal-Wallis test with Dunn's post-test. Differences were considered significant with a 5% significance level (p < 0 05). Curve fitting for dose-response curves was carried out using GraphPad 5 (GraphPad Software Inc., San Diego, California).
RESULTS
Characterization of ORZ Nanoformulations
In previous published work the optimization of the best experimental conditions for the incorporation of ORZ in liposomes and LNP was established and pharmaceutically acceptable formulations were achieved. 13 25 The incorporation parameters and physicochemical properties of the ORZ nanoformulations (liposomes and LNP) used in all in vitro and in vivo studies in this report are displayed in Table I . Regardless of differences in their structure, chemical composition and preparation methods, both nanoformulations present high ORZ loadings and high I.E. without significant statistical differences (p > 0 05). In addition both nanoformulations present a negative zeta potential and a similar granulometric distribution (p > 0 05) suitable for parenteral administration. The incorporation of ORZ did not affect the properties of the nanoformulations as unloaded ones exhibit similar results for particle size or zeta potential (p > 0 05).
In Vitro Biological Evaluation ORZ nanoformulations and Free-ORZ were evaluated in vitro for their toxicity to THP-1 human monocytic leukaemia cell line (macrophage like cell line), haemolytic activity to RBCs and antileishmanial activity. The antileishmanial activity was evaluated against L. infantum promastigote cultures as well as against the intracellular amastigote form using infected THP-1 cells.
Haemolytic Activity and Cytotoxicity
The evaluation of the in vitro potential adverse effects of ORZ formulations revealed that Free-ORZ exhibits haemolytic activity against RBCs (HC 50 of 425 M) and also cytotoxicity for THP-1 cells (CC 50 of 20 M) (Table II) . In contrast none of the ORZ nanoformulations evidenced either haemolytic activity or cytotoxic effects up to the highest concentrations tested (500 M and 25 M, respectively).
Activity Against Promastigotes and Intracellular Form of L. infantum
The in vitro antileishmanial activity assays showed that Free-ORZ was active against both the promastigote (IC 50 = 17 M) and the intracellular amastigote stage (IC 50 = 19 M) of the parasite (Table II) . As for the nanoformulations it was found that ORZ antileishmanial activity decreased against both parasite forms. This might be due to the less availability of ORZ to the culture medium as it is incorporated in nanoDDS. This behaviour was observed for both nanoformulations.
In Vivo Evaluation
The therapeutic activity of ORZ nanoformulations was evaluated in a murine model of VL to establish the best treatment regimens, including: number of administrations, ORZ dose-response relationship and influence of the lipid excipient. For these purposes LipORZ, LNP-ORZ and Free-ORZ were administered under different conditions to Balb/c mice infected with L. infantum. The PB was determined and compared to infected and untreated animals.
Comparison with Glucantime
® Figure 1 shows the PB in the liver and spleen of infected mice after 5 administrations of Lip-ORZ, Free-ORZ and a commercially available antileishmanial drug (Glucantime ® ) administrated under standard conditions described in the literature. 38 Glucantime ® and Lip-ORZ presented similar results in spleen, whereas in the liver Lip-ORZ induced a 97% PB reduction as compared to 81% for Glucantime ® even using a 2 fold higher administered dose (Fig. 1) .
Comparative Study of Lip and LNP-ORZ Nanoformulations
The therapeutic activities of both nanoformulations with Free-ORZ in liver and spleen were compared. The results displayed in Figure 2 (A) show significant PB reductions (p < 0 05) in the liver (89 and 84%) and spleen (84 and 91%) for Lip-ORZ and LNP-ORZ, respectively as compared to control group proving that both ORZ nanoformulations are highly efficient in the treatment of infected mice. For Free-ORZ we observed a significant PB reduction (p < 0 05) only in the spleen while no significant reduction was found in the liver. The therapeutic activity was also evaluated by calculating the growth index (GI), which represents the difference between the PB at the end and at the beginning of treatment (Fig. 2(B) ). . 38 Data are expressed as PB per gram of spleen ( ) and liver ( ); mean ± SD (n = 5).
* p < 0 05 as compared to control; * * p < 0 05 as compared to Free-ORZ. 
Lopes et al.
Liposomes versus LNP: Comparative Study of Lipid-Based Systems as Oryzalin Carriers
Effect of Number of Administrations
In order to determine if the therapeutic activity of ORZ formulations could be further improved we increased the number of administrations from 5 to 10. For this purpose we evaluated the PB in the liver and spleen after administration of Lip-ORZ and LNP-ORZ and Free-ORZ (Figs. 3(A) and (B) ).
Results show a significant and continuous increase in PB for the control group during the treatment period. The same PB evolution was observed for Free-ORZ in the liver, indicating that this formulation is not effective in fighting the infection for the same period. With respect to the nanoformulations, a significant reduction in PB was observed as compared to control in both organs and also for Free-ORZ in the spleen, regardless the number of administrations. Both nanoformulations and treatment schedules not only repressed PB growth but also reduced it to levels below those observed in the beginning of treatment. However, we expected that the 10 administrations would further decrease the PB of treated groups. As this was not observed the shorter treatment regimen was chosen for further studies as this schedule was less distressful for animals and less cost-effective.
Dose-Response Study
The ORZ dose-response curves for PB reduction in liver and spleen after 5 days treatment with ORZ nanoformulations and Free-ORZ are shown in Figures 4(A) and (B). The dose response curves for both ORZ nanoformulations, reached a plateau between 6.25 mg/kg and 12.5 mg/kg, either in liver or in spleen. However, different behaviours for each formulation in each organ were observed. In fact, LNP-ORZ resulted in a higher PB reduction than Lip-ORZ, in the spleen with a plateau at 6.25 mg/kg (86%), while for Lip-ORZ a plateau was only reached at 12.5 mg/kg (74%) (Fig. 4(A) ). In the liver a reverse situation was observed with a plateau at 6.25 mg/kg (95%) for Lip-ORZ and only at 12.5 mg/kg (82%) for LNP-ORZ (Fig. 4(B) ). Compared to the results obtained with ORZ nanoformulations, Free-ORZ elicited the lowest PB reduction for all ORZ doses tested. The increase of the administered dose from 6.25 mg/kg to 25 mg/kg gave rise to a concomitant reduction on the PB, reaching a maximum of 73% and 62% in spleen and in liver, respectively. Even at 25 mg/kg, Free-ORZ PB reduction was lower than the obtained with both nanoformulations at 6.25 mg/kg or 12.5 mg/kg. This means that LipORZ and LNP-ORZ are more active than Free-ORZ as observed by comparing the ED 50 values of all formulations (Figs. 4(A) and (B)).
Effect of Lipid Excipient
To clarify the possible effect of the lipid excipient on the ORZ therapeutic activity, nanoformulations with different lipid contents, for the same ORZ dose (6.25 mg/kg) were tested (Table III) . No significant differences (p > 0 05) on the PB were found between control and groups treated with unloaded liposomes and LNP. Moreover, using different lipid doses and the same ORZ dose no significant differences (p > 0 05) were observed on the PB in liver and in spleen. These results indicate that the antileishmanial effect arises from ORZ and not from the lipid carriers and also that this excipient does not interfere with the drug activity.
DISCUSSION
The increasing interest in dinitroanilines as chemotherapeutic agents is documented by the number of reports describing their in vitro antileishmanial activity. However the in vivo evaluation of these agents is rather scarce either for dinitroanilines in free form or incorporated in nanoDDS. We were the first to report the in vivo antileishmanial activity of liposomal TFL, a dinitroaniline incorporated in liposomes, in a L. donovani murine model 23 and in an experimental canine leishmaniasis. 24 More recently, ORZ, another dinitroaniline was incorporated in two lipid-based nanoDDS (Lip-ORZ and LNP-ORZ). These nanoformulations were characterized in terms of their physicochemical properties and biologically evaluated (haemolytic activity, toxicity towards macrophages). 13 25 The biodistribution of Lip-ORZ was also performed in healthy animals, proving that the incorporation in liposomes is essential for targeting liver and spleen. 13 At this stage it is crucial to evaluate the in vitro and more important the in vivo therapeutic efficacy of LipORZ and LNP-ORZ as possible nanopharmaceuticals against leishmaniasis, while comparing systematically the two nanoDDS as ORZ carriers.
As both nanoformulations were intended for parenteral administration all materials used in the preparation of Lip-ORZ and LNP-ORZ are pharmaceutically acceptable for this purpose. 39 In fact most of them are currently used in several commercialized parenteral formulations, including those for the treatment of leishmaniasis such as Fungizone ® (sodium deoxycholate) or Abelcet ® (DMPC and DMPG).
Another important aspect kept in mind was the control of particle size distribution and zeta potential, not only to allow their correct comparison, but also to meet the purpose of the study, as these characteristics will define in vitro and in vivo behaviour of ORZ nanoformulations. The size range chosen (160-220 nm) not only is suitable for parenteral administration but also for the uptake by the liver and spleen macrophages. 40 The highly negative zeta potential of both nanoformulations, obtained by a suitable lipid composition (high contents of negative phospholipids and surfactants), will also favour macrophage uptake, as intended. 40 Moreover the negative surface charge is expected to play an important role on nanoformulations stability by preventing particle aggregation due to electrostatic repulsion. 41 In spite of differences in raw materials and preparation methods between Lip-ORZ and LNP-ORZ they were very similar in the ability to incorporate ORZ with high I.E. (> 90%) and L.C. (≈ 30 g ORZ/mol of lipid or ≈ 5% w/w). As demonstrated in our previous studies, ORZ is incorporated within the lipid bilayer of liposomes, 13 whereas in LNP is incorporated both in the lipid matrix and in the surfactant layer surrounding it. 25 In both cases ORZ incorporation had no significant effect on size and zeta potential of the nanoformulations (Table I) .
After optimization of ORZ nanoformulations we proceeded to verify whether the incorporation was translated into an improvement of drug performance. This was confirmed by the reduction on the cytotoxicity and the absence of haemolytic activity after ORZ incorporation, demonstrating a rather protective role of nanoformulations to mammalian cells. Similar results were obtained with other antileishmanial drugs incorporated either in liposomes 42 43 or LNP. 28 These protective features may also explain the lower activity of Lip-ORZ and LNP-ORZ, observed against L. infantum promastigotes, since after incorporation ORZ is less available to interact with the parasite in culture. Nevertheless, incorporated ORZ retained its activity against intracellular amastigotes, the clinically relevant form of the parasite.
The comparative studies of ORZ nanoformulations was focused on the in vivo evaluation of therapeutic activity as in vitro studies are not always predictive of biological performance. Relevant aspects, such as number of administrations, ORZ dose-response relationship and effect of lipid excipient were explored in a murine model of VL. Among the parenteral routes of administration, i.v. was selected as it is one of the most widely used, in murine models, for the administration of antileishmanial drugs and nanoDDS. 44 45 Previous works have shown that the distribution of liposomes and LNP to liver and spleen was higher after i.v. as compared to i.p. and even s.c. administration. 46 47 Using this route of administration, the efficacy of Lip-ORZ was demonstrated as compared to Glucantime ® even at lower doses (Fig. 1) . Using the same treatment conditions, liposomes and LNP proved to enhance ORZ activity in the liver and spleen as indicated by an up to 3 fold PB reduction. This enhancement correlates well with the higher accumulation of ORZ nanoformulations observed in these organs as we demonstrated before. 13 While this was observed for nanoformulations with a particle size around 140 nm, in the present study ORZ nanoformulations accumulation is expected to be higher as it concomitantly increases with the particle size (160-220 nm), as described before. [48] [49] [50] Our strategy to further reduce PB by increasing the number of administrations with ORZ nanoformulations from 5 to 10 was not translated into an improved therapeutic effect (Fig. 3) . In fact 10 administrations did not lead to a further reduction in the PB as expected. Results show that ORZ nanoformulations were only able to arrest the PB increase observed in the control group, maintaining the values obtained after 5 administrations. This suggests that the concentration of ORZ present in the liver and spleen did not concomitantly increase with the number of administrations, probably due to hepatic and splenic saturation as described before. 51 52 The dose-response curves clearly demonstrate the improvement obtained by incorporation of ORZ in nanoformulations by a strong reduction of ED 50 values in both organs as compared to Free-ORZ. Reductions of 65 (Lip-ORZ) and 6 (LNP-ORZ) fold for liver and 3 (Lip-ORZ) and 11 (LNP-ORZ) fold for spleen were observed. This experiment also allowed concluding that lower doses of incorporated ORZ are enough to attain the maximal activity, as a plateau was reached between 6.25 and 12.5 mg/kg. The lowest dose of incorporated ORZ presented an activity similar to that of a 4 fold higher dose of Free-ORZ, confirming the superiority of the nanoformulated drug.
It is interesting to observe that each nanoformulation presents a different activity profile in each target organ. While higher activity was observed for LNP-ORZ in the spleen (4 fold lower ED 50 ), Lip-ORZ was more active in the liver (11 fold lower ED 50 ). As size and surface charge characteristics of both nanoformulations were similar, as well as the protocol for therapeutic activity evaluation, the results suggest differences in the biodistribution of the nanoformulations in these organs due to some other factors. One hypothesis could be the different rigidity of both nanoformulations, as Lip-ORZ presents a phase transition temperature of + 23 C, whereas LNP presents a lipid core of tripalmitin with a melting point of + 62 C. 13 25 In physiological conditions the liposomal bilayer will be in a fluid state while LNP remain in a solid state and thus less flexible. This rigidity/inflexibility of LNP will probably lead to a high retention in spleen, as the width of interendothelial cell slits in the spleen venous is approximately 200-250 nm. 53 54 The flexibility of Lip-ORZ makes them deformable enough to overcome splenic filtration. This hypothesis will be elucidated in near future after appropriate biodistribution profile evaluation. It was clarified that the antileishmanial activity is due to ORZ and not to the lipid excipients, as demonstrated by absence of any activity for the unloaded nanoformulations. Similar observations for lipid-based systems have been already reported in the literature. 55 
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CONCLUSIONS
The incorporation of ORZ either in liposomes or LNP with suitable physicochemical properties for in vivo administration allowed reducing the cytotoxicity and abolished the haemolytic activity evidenced by Free-ORZ. The ORZ nanoformulations also kept the antileishmanial intracellular activity. In vivo studies demonstrated that incorporation of ORZ in liposomes and in LNP clearly improved its pharmacological performance. There were no significant differences between both nanoformulations, except for the preferential activity found in each target organs. In future work, biodistribution profiles should be performed to elucidate this behaviour.
